Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records

Makoto Kakara, Hiroko Nomura, Mai Ezaki, Masato Fukae, Takeshi Hirota, Sunao Matsubayashi, Masaaki Hirakawa, Ichiro Ieiri

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus patients based on electronic medical records. Methods Information on patients was collected retrospectively from electronic medical records. Of the 4 DPP-4 inhibitors used, we focused on sitagliptin as it had the best time-response relationships. A physiological indirect response model was developed to describe changes in HbA1c levels. Results An indirect response model, based on the 1300 HbA1c levels of 160 patients, described the time course for the HbA1c-lowering effects of adding sitagliptin. The combination with pioglitazone decreased the HbA1c synthesis rate by 7.74% relative to without pioglitazone. Bayesian forecasting based on the final PDD model using the first two HbA1c observations, before and within 30 days after the addition of sitagliptin, gave a precise prediction of HbA1c-lowering effects individually. Conclusions Our PPD model quantitatively described the beneficial effects of combination therapy with pioglitazone and sitagliptin. The proposal methodology is also expected to be applicable to other medicines based on electronic medical records in clinical practice.

元の言語英語
ページ(範囲)1282-1286
ページ数5
ジャーナルJournal of Diabetes and Its Complications
30
発行部数7
DOI
出版物ステータス出版済み - 9 1 2016

Fingerprint

Electronic Health Records
pioglitazone
Type 2 Diabetes Mellitus
Hemoglobins
Population
Therapeutics
Sitagliptin Phosphate

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

これを引用

Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records. / Kakara, Makoto; Nomura, Hiroko; Ezaki, Mai; Fukae, Masato; Hirota, Takeshi; Matsubayashi, Sunao; Hirakawa, Masaaki; Ieiri, Ichiro.

:: Journal of Diabetes and Its Complications, 巻 30, 番号 7, 01.09.2016, p. 1282-1286.

研究成果: ジャーナルへの寄稿記事

@article{fdd497700cab419e8850e37b7ba35eb9,
title = "Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records",
abstract = "Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus patients based on electronic medical records. Methods Information on patients was collected retrospectively from electronic medical records. Of the 4 DPP-4 inhibitors used, we focused on sitagliptin as it had the best time-response relationships. A physiological indirect response model was developed to describe changes in HbA1c levels. Results An indirect response model, based on the 1300 HbA1c levels of 160 patients, described the time course for the HbA1c-lowering effects of adding sitagliptin. The combination with pioglitazone decreased the HbA1c synthesis rate by 7.74{\%} relative to without pioglitazone. Bayesian forecasting based on the final PDD model using the first two HbA1c observations, before and within 30 days after the addition of sitagliptin, gave a precise prediction of HbA1c-lowering effects individually. Conclusions Our PPD model quantitatively described the beneficial effects of combination therapy with pioglitazone and sitagliptin. The proposal methodology is also expected to be applicable to other medicines based on electronic medical records in clinical practice.",
author = "Makoto Kakara and Hiroko Nomura and Mai Ezaki and Masato Fukae and Takeshi Hirota and Sunao Matsubayashi and Masaaki Hirakawa and Ichiro Ieiri",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.jdiacomp.2016.06.009",
language = "English",
volume = "30",
pages = "1282--1286",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records

AU - Kakara, Makoto

AU - Nomura, Hiroko

AU - Ezaki, Mai

AU - Fukae, Masato

AU - Hirota, Takeshi

AU - Matsubayashi, Sunao

AU - Hirakawa, Masaaki

AU - Ieiri, Ichiro

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus patients based on electronic medical records. Methods Information on patients was collected retrospectively from electronic medical records. Of the 4 DPP-4 inhibitors used, we focused on sitagliptin as it had the best time-response relationships. A physiological indirect response model was developed to describe changes in HbA1c levels. Results An indirect response model, based on the 1300 HbA1c levels of 160 patients, described the time course for the HbA1c-lowering effects of adding sitagliptin. The combination with pioglitazone decreased the HbA1c synthesis rate by 7.74% relative to without pioglitazone. Bayesian forecasting based on the final PDD model using the first two HbA1c observations, before and within 30 days after the addition of sitagliptin, gave a precise prediction of HbA1c-lowering effects individually. Conclusions Our PPD model quantitatively described the beneficial effects of combination therapy with pioglitazone and sitagliptin. The proposal methodology is also expected to be applicable to other medicines based on electronic medical records in clinical practice.

AB - Aim To develop a population pharmacodynamic (PPD) model describing the time course for the hemoglobin A1c (HbA1c)-lowering effects of adding treatment of DPP-4 inhibitors and to assess the efficacy of combination therapy in type 2 diabetes mellitus patients based on electronic medical records. Methods Information on patients was collected retrospectively from electronic medical records. Of the 4 DPP-4 inhibitors used, we focused on sitagliptin as it had the best time-response relationships. A physiological indirect response model was developed to describe changes in HbA1c levels. Results An indirect response model, based on the 1300 HbA1c levels of 160 patients, described the time course for the HbA1c-lowering effects of adding sitagliptin. The combination with pioglitazone decreased the HbA1c synthesis rate by 7.74% relative to without pioglitazone. Bayesian forecasting based on the final PDD model using the first two HbA1c observations, before and within 30 days after the addition of sitagliptin, gave a precise prediction of HbA1c-lowering effects individually. Conclusions Our PPD model quantitatively described the beneficial effects of combination therapy with pioglitazone and sitagliptin. The proposal methodology is also expected to be applicable to other medicines based on electronic medical records in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84990937723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990937723&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2016.06.009

DO - 10.1016/j.jdiacomp.2016.06.009

M3 - Article

C2 - 27338508

AN - SCOPUS:84990937723

VL - 30

SP - 1282

EP - 1286

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 7

ER -